Search results
Biogen hires former Sanofi head Viehbacher as CEO
Reuters via Yahoo Finance· 2 years ago(Reuters) -Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the...
Biogen tabs veteran pharma leader Viehbacher as next CEO
Associated Press via Yahoo News· 2 years agoBiogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug...
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
Zacks via Yahoo Finance· 8 months agoBioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company...
Biogen CEO bets on Alzheimer's drug, pipeline to return to growth
Reuters via Yahoo Finance· 1 year ago(Reuters) -Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking...
Biogen says growth is coming, but won’t specify when
BioPharma Dive via Yahoo Finance· 7 months agoCEO Chris Viehbacher said the company has “the elements to think about a return to topline growth.” Yet, that goal hinges on the successful...
Musk's acrimonious Twitter bid heads for business school case study immortalisation
Reuters via Yahoo Finance· 2 years agoElon Musk's $44 billion Twitter takeover saga comes with all the drama necessary to be immortalised...
Q3 2023 Inovio Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 months agoParticipants Thomas Hong; IR; Inovio Pharmaceuticals, Inc. Jacqui Shea; President & CEO; Inovio Pharmaceuticals, Inc. Mike Sumner; Chief Medical Officer; Inovio Pharmaceuticals, Inc. Mark Twyman ...
2022 Massachusetts Primary: Meet the candidates
WFXT via Yahoo News· 2 years agoREPUBLICAN CANDIDATES FOR NOMINATION Geoff Diehl Republican Candidate for Governor Diehl is a former state representative. He served from 2011-2018...
Biogen: Don’t expect any big acquisitions this year
BioPharma Dive via Yahoo Finance· 2 months agoWhile the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Barrons.com· 3 months agoBARRON'S COVER - MAIN Understanding the products from pharmaceutical companies could be the most...
